Conceptual Entity
ReNeuron Exits London Stock Exchange Amid Jacobio’s China Rights Deal
ReNeuron, Jacobio, London Stock Exchange, AIM, China rights deal, biotech, stem cell therapy
Galapagos Investor Seeks to Influence Company Control, Citing Undervaluation
Galapagos, investor influence, undervaluation, biotech, corporate control
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection
COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.
LEO Pharma’s Acquisition of Timber Pharmaceuticals’ Assets Faces Setback Due to Late-Stage Study Failure
LEO Pharma, Timber Pharmaceuticals, TMB-001, congenital ichthyosis, late-stage study failure, asset acquisition
Sanofi Deprioritizes Four Assets, Including Mid-Stage Dwarfism Treatment
Sanofi, dwarfism, mid-stage treatment, asset deprioritization, rare disease, achondroplasia
FDA Issues Warning Letter to Indian CDMO Brassica for Data Falsification and Poor Hygiene Practices
FDA, Warning Letter, Brassica Pharma, Data Falsification, Poor Hygiene, Indian CDMO, CGMP Violations
Asceneuron Secures $100 Million in Series C Funding for Dementia Asset Development
Asceneuron, Series C Funding, Dementia Asset, Novo Ventures, Biotech Investment
Grifols Founding Family and Brookfield Plan to Take Drugmaker Private
Grifols, Brookfield, Private Equity, Takeover Bid, Spanish Drugmaker, Nasdaq, Spanish Stock Exchange
TRACON Pharmaceuticals Discontinues Envafolimab Development, Explores Strategic Options
TRACON Pharmaceuticals, Envafolimab, Oncology, Clinical Trial, Strategic Options, Mergers, Acquisitions, Asset Sales
Medical Devices Outshine Rx Drugs at Cannes Lions, Highlighting Shift in Customer Focus
Cannes Lions, Medical Devices, Rx Drugs, Customer Focus, Jury President